Phage Therapy Beyond Static Pharmaceuticals: A Framework for Controlled Evolutionary Platforms

Rising antimicrobial resistance has revived global interest in phage therapy, yet its transition to standard clinical practice remains slow. This challenge is not solely due to a lack of efficacy. Instead, we face a fundamental conceptual barrier caused by an “evaluation mismatch.” Traditional regulations treat phages as static chemical molecules—like taking a “snapshot.” However, biologically, phages are dynamic, evolving populations—more like a living “movie.” In this review, we use Schrödinger’s cat metaphor to explain this reality: phage variability is not a defect, but an essential feature. To bridge this gap, we propose a Controlled Evolutionary Platform. By distinguishing between a fixed “Safety Core” and a fluctuating “Adaptive Periphery,” we can manage viral evolution rather than trying to stop it. Ultimately, to integrate phages into modern medicine, we must redefine “consistency”: shifting our focus from preserving a fixed genetic sequence to ensuring the reliable performance of population dynamics.